Related Experiment Video
Updated: May 5, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
Perceptions regarding genetic testing in populations at risk for nephropathy.
Barry I Freedman1, Alison J Fletcher, Vivek R Sanghani
1Department of Internal Medicine - Section on Nephrology, Wake Forest School of Medicine, Wake Forest University, Winston-Salem, N.C., USA.
African-Americans and European-Americans at risk for kidney disease share similar views on genetic testing. Most participants desired to know their genetic risk and share this information with family, regardless of treatment availability.
Area of Science:
- Genetics
- Nephrology
- Public Health
Background:
- Genetic predisposition to kidney diseases varies across ancestral populations.
- Returning genetic test results to research participants remains a complex ethical issue.
- This study investigated the perspectives of African-Americans (AAs) and European-Americans (EAs) at risk for end-stage kidney disease regarding genetic testing.
Purpose of the Study:
- To compare the attitudes of African-Americans and European-Americans towards the value and utility of genetic testing for kidney disease risk.
- To understand participant preferences for receiving genetic test results, irrespective of available interventions.
- To assess the likelihood of participants sharing genetic risk information with family members.
Main Methods:
- A survey on attitudes toward genetic testing was administered to 130 individuals (64 AA, 66 EA) with a family history of kidney disease requiring dialysis.
- Fisher's exact test was employed to analyze differences in attitudes between the two population groups.
Main Results:
- Both AAs and EAs expressed a strong desire to know their genetic test results, even if no treatments were available (90% AA, 82% EA).
- A high percentage of participants from both groups indicated they would inform family members about their genetic risk status, whether positive or negative (87-92% AA, 88-89% EA).
- Age differed significantly between groups (p=0.04), but familial relationships were similar (p=0.22).
Conclusions:
- Attitudes regarding the acquisition and utilization of genetic test results for kidney disease research are comparable between AAs and EAs.
- The majority of individuals at risk for end-stage kidney disease want to receive genetic information and share it with their families.
- Findings have significant implications for clinical practice, research study design, and the informed consent process in genetic research.
More Related Videos
Related Concept Videos
Principles of Pharmacogenetics: Types of Genetic Variants
Pharmacogenomics: Identification of New Drug Targets
Pharmacogenetics and Pharmacogenomics: Overview
Diabetic Nephropathy
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Pharmacogenetics of Drug Metabolism: Overview

